These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Possible new role of vascular endothelial growth factor-D during the acute phase of Kawasaki disease. Hirono K; Ichida F Circ J; 2011; 75(6):1324-5. PubMed ID: 21532175 [No Abstract] [Full Text] [Related]
24. The treatment of Kawasaki disease. Sagraves R J Pediatr Health Care; 1993; 7(6):278-82. PubMed ID: 8106928 [No Abstract] [Full Text] [Related]
25. Incomplete Kawasaki disease: a pediatric diagnostic conflict. Celik U; Alhan E; Arabaci F Anadolu Kardiyol Derg; 2007 Sep; 7(3):343-4. PubMed ID: 17785242 [No Abstract] [Full Text] [Related]
30. Treatment of a Jehovah's Witness with immune globulin: case of a child with Kawasaki syndrome. Roy-Bornstein C; Sagor LD; Roberts KB Pediatrics; 1994 Jul; 94(1):112-3. PubMed ID: 8008516 [No Abstract] [Full Text] [Related]
31. Kawasaki disease--treatment with intravenous immunoglobulin during the acute stage. Singh S; Kumar L Indian Pediatr; 1996 Aug; 33(8):689-92. PubMed ID: 8979554 [No Abstract] [Full Text] [Related]
32. Pulmonary presentation of Kawasaki disease: an unusual occurrence. Vaidya PC; Narayanan K; Suri D; Rohit MK; Gupta A; Singh S; Singh M Int J Rheum Dis; 2017 Dec; 20(12):2227-2229. PubMed ID: 26662672 [No Abstract] [Full Text] [Related]
33. Efficacy and safety of immunoglobulin retreatment in Kawasaki disease. Falcini F; Ermini M; Trapani S; Taccetti G J Pediatr; 1994 Oct; 125(4):672-3. PubMed ID: 7931898 [No Abstract] [Full Text] [Related]
34. Epidemiological investigation of Kawasaki disease in Jilin province of China from 2000 to 2008. Piao JH; Jin LH; Lv J; Zhou Y; Jin CJ; Jin ZY Cardiol Young; 2010 Aug; 20(4):426-32. PubMed ID: 20420740 [TBL] [Abstract][Full Text] [Related]
35. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Shiraishi T; Yamamoto T Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420 [TBL] [Abstract][Full Text] [Related]
36. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis]. Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521 [TBL] [Abstract][Full Text] [Related]
38. Differential protein analysis of serum exosomes post-intravenous immunoglobulin therapy in patients with Kawasaki disease. Zhang L; Song QF; Jin JJ; Huang P; Wang ZP; Xie XF; Gu XQ; Gao XJ; Jia HL Cardiol Young; 2017 Nov; 27(9):1786-1796. PubMed ID: 28803590 [TBL] [Abstract][Full Text] [Related]
39. The effect of intravenous immunoglobulin on lymphocyte populations in children with Kawasaki syndrome. Saulsbury FT Clin Exp Rheumatol; 1992; 10(6):617-20. PubMed ID: 1483316 [TBL] [Abstract][Full Text] [Related]